marketcaparena
Search

    ADPT

    Adaptive Biotechnologies Corp

    Company overview

    Market capitalization
    $4.55B
    Employees
    624
    Latest publication
    2026-09-29
    About Adaptive Biotechnologies Corp

    Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20252025-09-30 · USD
    Total Revenue71,553,000USD93,973,000USD
    Cost Of Revenue20,165,000USD18,157,000USD
    Gross Profit51,388,000USD75,816,000USD
    Research Development19,153,000USD23,669,000USD
    Selling And Marketing Expenses26,414,000USD23,470,000USD
    General And Administrative Expenses21,168,000USD—
    Other Operating Expenses423,000USD—
    Total Operating Expenses67,158,000USD65,526,000USD
    Operating Income-15,770,000USD10,290,000USD
    Interest Expense2,694,000USD2,971,000USD
    Net Income-39,941,000USD9,546,000USD
    Minority Interest-153,000USD1,000USD
    Selling General Administrative—17,959,000USD
    Interest Income—2,226,000USD
    Net Interest Income—-745,000USD
    Income Before Tax—9,546,000USD
    Net Income From Continuing Ops—9,545,000USD
    Ebit—12,517,000USD
    Ebitda—16,922,000USD
    Depreciation And Amortization—4,405,000USD
    Reconciled Depreciation—4,405,000USD
    Total Other Income Expense Net—-744,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets640,678,000USD505,943,000USD512,736,000USD490,610,000USD496,637,000USD510,852,000USD539,376,000USD558,506,000USD
    Cash And Equivalents169,873,000USD———————
    Total Current Assets420,563,000USD291,807,000USD300,185,000USD281,435,000USD261,856,000USD256,489,000USD283,752,000USD308,345,000USD
    Other Current Assets16,298,000USD13,952,000USD13,020,000USD12,412,000USD11,295,000USD10,798,000USD11,287,000USD12,247,000USD
    Other Non Current Assets1,478,000USD———————
    Total Liabilities490,016,000USD———————
    Total Current Liabilities87,712,000USD87,011,000USD89,915,000USD83,361,000USD92,141,000USD87,809,000USD98,053,000USD87,627,000USD
    Other Current Liabilities10,651,000USD———————
    Other Non Current Liabilities20,000USD———————
    Total Stockholder Equity142,914,000USD216,340,000USD218,793,000USD204,435,000USD179,717,000USD190,423,000USD202,709,000USD223,773,000USD
    Total Equity Including Noncontrolling Interest150,662,000USD———————
    Short Long Term Debt0USD———————
    Long Term Debt0USD———————
    Deferred Revenue53,255,000USD———————
    Deferred Revenue Non Current608,000USD———————
    Net Receivables49,513,000USD48,315,000USD50,365,000USD46,321,000USD44,285,000USD43,583,000USD41,731,000USD40,814,000USD
    Inventory10,497,000USD11,206,000USD9,820,000USD9,933,000USD8,403,000USD8,684,000USD8,440,000USD11,955,000USD
    Property Plant Equipment Net68,573,000USD71,022,000USD74,723,000USD79,486,000USD84,393,000USD88,434,000USD94,383,000USD97,844,000USD
    Goodwill118,972,000USD———————
    Accounts Payable5,241,000USD9,615,000USD6,467,000USD10,267,000USD6,908,000USD6,362,000USD7,265,000USD7,351,000USD
    Short Term Debt8,823,000USD14,317,000USD13,562,000USD9,442,000USD9,957,000USD10,462,000USD10,239,000USD10,021,000USD
    Common Stock16,000USD16,000USD15,000USD15,000USD15,000USD15,000USD14,000USD14,000USD
    Retained Earnings-1,423,144,000USD-1,383,356,000USD-1,363,323,000USD-1,349,744,000USD-1,359,290,000USD-1,333,676,000USD-1,303,824,000USD-1,270,132,000USD
    Accumulated Other Comprehensive Income-212,000USD-28,000USD253,000USD211,000USD73,000USD134,000USD166,000USD497,000USD
    Intangible Assets—1,307,000USD1,726,000USD2,155,000USD2,583,000USD3,006,000USD3,425,000USD3,853,000USD
    Total Liab—281,702,000USD287,735,000USD286,357,000USD317,101,000USD320,631,000USD336,891,000USD334,932,000USD
    Other Current Liab—13,682,000USD24,692,000USD22,315,000USD19,975,000USD16,180,000USD24,684,000USD18,399,000USD
    Capital Stock—16,000USD15,000USD15,000USD15,000USD15,000USD14,000USD14,000USD
    Good Will—118,972,000USD118,972,000USD118,972,000USD118,972,000USD118,972,000USD118,972,000USD118,972,000USD
    Cash—77,581,000USD70,495,000USD55,034,000USD43,163,000USD50,646,000USD47,920,000USD38,084,000USD
    Cash And Short Term Investments—218,334,000USD226,980,000USD212,769,000USD197,873,000USD193,424,000USD222,294,000USD243,329,000USD
    Current Deferred Revenue—49,397,000USD45,194,000USD41,337,000USD55,301,000USD54,805,000USD55,689,000USD51,856,000USD
    Net Debt—130,600,000USD210,089,000USD26,769,000USD41,207,000USD36,254,000USD41,467,000USD53,741,000USD
    Short Long Term Debt Total—208,181,000USD280,584,000USD81,803,000USD84,370,000USD86,900,000USD89,387,000USD91,825,000USD
    Long Term Investments—18,889,000USD13,234,000USD4,037,000USD24,100,000USD39,355,000USD33,660,000USD23,866,000USD
    Short Term Investments—140,753,000USD156,485,000USD157,735,000USD154,710,000USD142,778,000USD174,374,000USD205,245,000USD
    Property Plant Equipment Gross—71,022,000USD170,509,000USD79,486,000USD84,393,000USD88,434,000USD182,200,000USD97,844,000USD
    Common Stock Shares Outstanding—38,880,262shares38,281,780shares40,790,527shares38,020,571shares149,195,000shares147,101,648shares147,516,000shares
    Non Current Assets Total—214,136,000USD212,551,000USD209,175,000USD234,781,000USD254,363,000USD255,624,000USD250,161,000USD
    Non Current Liabilities Total—194,691,000USD197,820,000USD202,996,000USD224,960,000USD232,822,000USD238,838,000USD247,305,000USD
    Non Current Liabilities Other—124,769,000USD126,586,000USD129,429,000USD130,515,000USD131,570,000USD132,434,000USD132,720,000USD
    Non Currrent Assets Other—22,835,000USD1,207,000USD1,836,000USD4,733,000USD4,596,000USD5,184,000USD5,626,000USD
    Net Working Capital—204,796,000USD210,270,000USD198,074,000USD169,715,000USD168,680,000USD185,699,000USD220,718,000USD
    Unclassified Non Current Assets—-18,889,000USD2,689,000USD2,689,000USD————
    Unclassified Non Current Liabilities—69,922,000USD71,234,000USD73,567,000USD94,445,000USD101,252,000USD106,404,000USD114,585,000USD
    Unclassified Equity—1,599,692,000USD1,581,833,000USD1,553,938,000USD1,538,904,000USD1,523,935,000USD1,506,339,000USD1,493,380,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets512,736,000USD539,376,000USD661,134,000USD856,617,000USD923,344,000USD1,116,414,000USD912,302,000USD332,688,000USD
    Intangible Assets1,726,000USD3,425,000USD5,128,000USD6,827,000USD8,526,000USD10,225,000USD11,928,000USD13,626,000USD
    Other Current Assets13,020,000USD11,287,000USD11,370,000USD9,440,000USD13,015,000USD14,535,000USD14,079,000USD3,055,000USD
    Total Liab287,735,000USD336,891,000USD352,856,000USD392,519,000USD319,242,000USD373,148,000USD341,263,000USD590,800,000USD
    Total Stockholder Equity218,793,000USD202,709,000USD308,399,000USD464,165,000USD603,992,000USD743,266,000USD571,039,000USD-258,112,000USD
    Other Current Liab24,692,000USD24,684,000USD22,223,000USD28,165,000USD24,594,000USD23,345,000USD10,804,000USD8,312,000USD
    Common Stock15,000USD14,000USD14,000USD14,000USD14,000USD14,000USD12,000USD1,000USD
    Capital Stock15,000USD14,000USD14,000USD14,000USD14,000USD14,000USD12,000USD1,000USD
    Retained Earnings-1,363,323,000USD-1,303,824,000USD-1,144,332,000USD-919,082,000USD-718,891,000USD-511,612,000USD-365,478,000USD-295,908,000USD
    Good Will118,972,000USD118,972,000USD118,972,000USD118,972,000USD118,972,000USD118,972,000USD118,972,000USD118,972,000USD
    Cash70,495,000USD47,920,000USD65,064,000USD90,030,000USD139,065,000USD123,436,000USD96,576,000USD55,030,000USD
    Cash And Short Term Investments226,980,000USD222,294,000USD346,401,000USD498,196,000USD353,061,000USD688,269,000USD576,866,000USD165,018,000USD
    Total Current Assets300,185,000USD283,752,000USD410,188,000USD562,146,000USD402,748,000USD726,914,000USD612,690,000USD180,718,000USD
    Total Current Liabilities89,915,000USD98,053,000USD88,015,000USD109,788,000USD113,807,000USD105,197,000USD78,313,000USD22,800,000USD
    Current Deferred Revenue45,194,000USD55,689,000USD48,630,000USD64,115,000USD80,460,000USD73,319,000USD60,994,000USD12,695,000USD
    Net Debt210,089,000USD41,467,000USD33,708,000USD17,972,000USD-27,325,000USD-15,574,000USD-59,969,000USD506,164,000USD
    Short Term Debt13,562,000USD10,239,000USD9,384,000USD9,230,000USD5,055,000USD3,529,000USD—0USD
    Short Long Term Debt Total280,584,000USD89,387,000USD98,772,000USD108,002,000USD111,740,000USD107,862,000USD36,607,000USD561,194,000USD
    Long Term Investments13,234,000USD33,660,000USD0USD0USD217,145,000USD118,525,000USD105,435,000USD0USD
    Short Term Investments156,485,000USD174,374,000USD281,337,000USD408,166,000USD213,996,000USD564,833,000USD480,290,000USD109,988,000USD
    Net Receivables50,365,000USD41,731,000USD37,969,000USD40,057,000USD17,409,000USD10,047,000USD12,676,000USD4,807,000USD
    Inventory9,820,000USD8,440,000USD14,448,000USD14,453,000USD19,263,000USD14,063,000USD9,069,000USD7,838,000USD
    Accounts Payable6,467,000USD7,265,000USD7,719,000USD8,084,000USD3,307,000USD3,237,000USD4,453,000USD1,793,000USD
    Property Plant Equipment Net74,723,000USD94,383,000USD120,323,000USD164,210,000USD172,940,000USD139,042,000USD60,355,000USD19,125,000USD
    Property Plant Equipment Gross170,509,000USD182,200,000USD193,557,000USD164,210,000USD172,940,000USD139,042,000USD60,355,000USD19,125,000USD
    Accumulated Other Comprehensive Income253,000USD166,000USD215,000USD-4,116,000USD-1,137,000USD893,000USD671,000USD-107,000USD
    Common Stock Shares Outstanding37,930,485shares36,775,500shares36,095,824shares35,628,979shares140,354,915shares131,216,467shares124,341,418shares105,433,645shares
    Non Current Assets Total212,551,000USD255,624,000USD250,946,000USD294,471,000USD520,596,000USD389,500,000USD299,612,000USD151,970,000USD
    Non Current Liabilities Total197,820,000USD238,838,000USD264,841,000USD282,731,000USD205,435,000USD267,951,000USD262,950,000USD568,000,000USD
    Non Current Liabilities Other126,586,000USD132,434,000USD130,660,000USD125,360,000USD205,435,000USD267,951,000USD93,000USD—
    Non Currrent Assets Other1,207,000USD5,184,000USD6,523,000USD4,462,000USD3,013,000USD2,736,000USD2,922,000USD247,000USD
    Net Working Capital210,270,000USD185,699,000USD322,173,000USD452,358,000USD288,941,000USD621,717,000USD534,377,000USD157,918,000USD
    Unclassified Non Current Assets2,689,000USD——-4,462,000USD——-39,529,000USD—
    Unclassified Non Current Liabilities71,234,000USD106,404,000USD134,181,000USD-26,588,000USD-98,750,000USD-163,618,000USD36,514,000USD560,858,000USD
    Unclassified Equity1,581,833,000USD1,506,339,000USD1,452,488,000USD1,387,335,000USD1,323,992,000USD1,253,957,000USD935,822,000USD37,901,000USD
    Other Liab———183,959,000USD98,750,000USD163,618,000USD226,343,000USD6,806,000USD
    Other Assets———4,462,000USD3,013,000USD2,736,000USD39,529,000USD247,000USD
    Net Tangible Assets———338,366,000USD476,494,000USD614,069,000USD440,139,000USD-390,710,000USD
    Unclassified Current Liabilities—————1,767,000USD2,062,000USD—
    Deferred Long Term Liab———————0USD
    Short Long Term Debt———————0USD
    Long Term Debt———————336,000USD
    Additional Paid In Capital———————0USD
    Treasury Stock———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-20,015,000USD-13,579,000USD9,546,000USD-25,593,000USD-29,852,000USD-33,717,000USD-32,070,999USD-46,222,000USD
    Depreciation3,837,000USD4,195,000USD4,405,000USD4,502,000USD4,731,000USD4,448,000USD4,591,000USD5,003,000USD
    Stock Based Compensation11,928,000USD12,720,000USD13,257,000USD13,359,000USD12,147,000USD12,832,000USD13,522,000USD12,958,000USD
    Other Non Cash Items1,008,000USD1,170,000USD12,790,000USD607,000USD12,780,000USD893,000USD13,441,999USD21,090,000USD
    Change To Account Receivables2,050,000USD-5,544,000USD-536,000USD-702,000USD-1,864,000USD-899,000USD-5,204,000USD6,411,000USD
    Change To Inventory-1,315,000USD-10,000USD-1,347,000USD95,000USD264,000USD3,382,000USD1,697,000USD-818,000USD
    Change In Working Capital-6,295,000USD-2,451,000USD-33,868,000USD-5,305,000USD-16,143,000USD3,053,000USD-13,027,000USD2,826,000USD
    Total Cash From Operating Activities-9,537,000USD2,055,000USD-7,127,000USD-12,430,000USD-28,484,000USD-12,491,000USD-27,065,000USD-17,303,000USD
    Capital Expenditures-796,000USD-636,000USD-409,000USD-655,000USD-1,259,000USD-80,000USD-344,000USD-1,729,000USD
    Free Cash Flow-10,333,000USD1,419,000USD-7,536,000USD-13,085,000USD-29,743,000USD-12,571,000USD-27,409,000USD-19,032,000USD
    Investments9,939,000USD-7,616,000USD17,283,000USD3,346,000USD25,573,000USD22,119,000USD5,287,000USD5,877,000USD
    Total Cashflows From Investing Activities9,143,000USD-8,252,000USD17,283,000USD3,346,000USD25,573,000USD22,119,000USD5,287,000USD5,877,000USD
    Total Cash From Financing Activities7,500,000USD21,658,000USD1,684,000USD1,610,000USD5,451,000USD127,000USD40,000USD30,000USD
    Change In Cash7,106,000USD15,461,000USD11,871,000USD-7,474,000USD2,726,000USD9,755,000USD-21,740,000USD-11,409,000USD
    Begin Period Cash Flow73,184,000USD57,723,000USD43,163,000USD53,357,000USD47,920,000USD41,062,000USD59,824,000USD71,233,000USD
    End Period Cash Flow80,290,000USD73,184,000USD55,034,000USD45,883,000USD50,646,000USD50,817,000USD38,084,000USD59,824,000USD
    Other Cashflows From Financing Activities7,500,000USD12,524,000USD1,684,000USD1,610,000USD5,451,000USD127,000USD40,000USD30,000USD
    Unclassified Financing Cash Flow—9,134,000USD——————
    Unclassified Operating Cash Flow——-13,257,000USD—-12,147,000USD—-13,522,000USD-12,958,000USD
    Unclassified Investing Cash Flow————1,259,000USD——-5,877,000USD
    Other Cashflows From Investing Activities———————7,606,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-59,499,000USD-159,595,000USD-225,250,000USD-200,191,000USD-207,279,000USD-146,227,000USD-68,606,000USD-46,447,000USD
    Depreciation17,833,000USD19,256,000USD22,231,000USD28,147,000USD20,981,000USD8,472,000USD7,791,000USD6,000,000USD
    Stock Based Compensation51,483,000USD53,610,000USD62,908,000USD55,477,000USD43,251,000USD24,761,000USD13,124,000USD11,149,000USD
    Other Non Cash Items1,964,000USD8,971,000USD92,878,000USD59,645,000USD50,387,000USD3,337,000USD43,000USD5,000USD
    Change To Account Receivables-8,646,000USD-3,744,000USD2,032,000USD-22,648,000USD-7,362,000USD2,613,000USD-7,817,000USD775,000USD
    Change To Inventory-998,000USD1,938,000USD-2,838,000USD817,000USD-5,200,000USD-4,994,000USD-1,231,000USD-3,046,000USD
    Change In Working Capital-57,767,000USD-17,454,000USD-46,183,000USD-71,546,000USD-56,816,000USD-40,799,000USD254,933,000USD-1,723,000USD
    Total Cash From Operating Activities-45,986,000USD-95,212,000USD-156,324,000USD-183,945,000USD-192,727,000USD-149,683,000USD205,404,000USD-32,259,000USD
    Capital Expenditures-2,959,000USD-3,664,000USD-10,697,000USD-16,349,000USD-61,746,000USD-18,803,000USD-11,200,000USD-6,318,000USD
    Free Cash Flow-48,945,000USD-98,876,000USD-167,021,000USD-200,294,000USD-254,473,000USD-168,486,000USD194,204,000USD-38,577,000USD
    Investments40,909,000USD77,792,000USD28,896,000USD2,905,000USD242,956,000USD-98,241,000USD-470,497,000USD7,035,000USD
    Total Cashflows From Investing Activities37,950,000USD77,792,000USD129,646,999USD2,905,000USD181,210,000USD-117,044,000USD-481,697,000USD736,000USD
    Total Cash From Financing Activities30,403,000USD241,000USD2,245,000USD132,264,999USD27,146,000USD293,587,000USD319,916,000USD1,248,000USD
    Change In Cash22,367,000USD-17,179,000USD-24,966,001USD-49,035,000USD15,629,000USD26,860,000USD43,623,000USD-30,275,000USD
    Begin Period Cash Flow50,817,000USD67,996,000USD90,030,000USD139,065,000USD123,436,000USD98,714,000USD55,091,000USD85,366,000USD
    End Period Cash Flow73,184,000USD50,817,000USD65,063,999USD90,030,000USD139,065,000USD125,574,000USD98,714,000USD55,091,000USD
    Other Cashflows From Financing Activities30,403,000USD241,000USD2,245,000USD7,890,000USD429,000USD21,427,000USD-934,000USD1,248,000USD
    Unclassified Investing Cash Flow—3,664,000USD111,448,000USD-2,905,000USD-181,210,000USD98,241,000USD470,497,000USD—
    Other Cashflows From Investing Activities——-1USD19,254,000USD181,210,000USD-98,241,000USD-470,497,000USD19,000USD
    Unclassified Operating Cash Flow——-62,908,000USD-55,477,000USD-43,251,000USD——-1,243,000USD
    Change To Liabilities———7,111,000USD3,940,000USD7,495,000USD273,076,000USD1,536,000USD
    Net Borrowings———124,375,000USD0USD——0USD
    Sale Purchase Of Stock———7,890,000USD26,717,000USD293,587,000USD324,905,000USD1,268,000USD
    Issuance Of Capital Stock———0USD0USD272,160,000USD320,850,000USD0USD
    Cash And Cash Equivalents Changes———-48,775,000USD15,629,000USD26,860,000USD——
    Unclassified Financing Cash Flow———-7,890,001USD—-21,427,000USD-4,055,000USD-1,268,000USD
    Dividends Paid———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductCollaboration Revenue0USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRegulatory Milestone Revenue0USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductService And Licensing Revenue5,385,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductServices66,168,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentImmune Medicine Business5,385,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentMrd Business66,168,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductCollaboration Revenue0USD0001193125-26-206546
    Q1 2026Quarterly · 2026-03-31ProductRegulatory Milestone Revenue9,000,000USD0001193125-26-206546
    Q1 2026Quarterly · 2026-03-31ProductService And Licensing Revenue3,781,000USD0001193125-26-206546
    Q1 2026Quarterly · 2026-03-31ProductServices58,093,000USD0001193125-26-206546
    Q1 2026Quarterly · 2026-03-31SegmentImmune Medicine Business3,781,000USD0001193125-26-206546
    Q1 2026Quarterly · 2026-03-31SegmentMrd Business67,093,000USD0001193125-26-206546
    Q4 2025Quarterly · 2025-12-31SegmentImmune Medicine Business9,794,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentMrd Business61,887,000USDLegacy provider
    FY 2025Yearly · 2025-12-31SegmentImmune Medicine Business64,642,000USD0001193125-26-076902
    FY 2025Yearly · 2025-12-31SegmentMrd Business212,334,000USD0001193125-26-076902
    Q3 2025Quarterly · 2025-09-30SegmentImmune Medicine Business37,185,000USD0001193125-25-267061
    Q3 2025Quarterly · 2025-09-30SegmentMrd Business56,788,000USD0001193125-25-267061
    Q2 2025Quarterly · 2025-06-30SegmentImmune Medicine Business8,941,000USD0000950170-25-103120
    Q2 2025Quarterly · 2025-06-30SegmentMrd Business49,938,000USD0000950170-25-103120
    Q1 2025Quarterly · 2025-03-31ProductCollaboration Revenue3,600,000USD0001193125-26-206546
    Q1 2025Quarterly · 2025-03-31ProductRegulatory Milestone Revenue4,500,000USD0001193125-26-206546
    Q1 2025Quarterly · 2025-03-31ProductServices44,343,000USD0001193125-26-206546
    Q1 2025Quarterly · 2025-03-31SegmentImmune Medicine Business8,722,000USD0001193125-26-206546
    Q1 2025Quarterly · 2025-03-31SegmentMrd Business43,721,000USD0001193125-26-206546
    Q4 2024Quarterly · 2024-12-31SegmentImmune Medicine Business7,310,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentMrd Business40,149,000USDLegacy provider
    FY 2024Yearly · 2024-12-31SegmentImmune Medicine Business33,428,000USD0001193125-26-076902
    FY 2024Yearly · 2024-12-31SegmentMrd Business145,529,000USD0001193125-26-076902
    Q3 2024Quarterly · 2024-09-30SegmentImmune Medicine Business8,965,000USD0001193125-25-267061
    Q3 2024Quarterly · 2024-09-30SegmentMrd Business37,470,000USD0001193125-25-267061
    Q4 2023Quarterly · 2023-12-31ProductCollaboration Revenue7,911,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductServices37,873,000USDLegacy provider
    FY 2023Yearly · 2023-12-31SegmentImmune Medicine Business67,537,000USD0001193125-26-076902
    FY 2023Yearly · 2023-12-31SegmentMrd Business102,739,000USD0001193125-26-076902
    FY 2023Yearly · 2023-12-31ProductCollaboration Revenue42,578,000USD0000950170-24-023095
    FY 2023Yearly · 2023-12-31ProductImmune Medicine Service Revenue600,000USD0000950170-24-023095
    FY 2023Yearly · 2023-12-31ProductServices127,698,000USD0000950170-24-023095
    Q3 2023Quarterly · 2023-09-30ProductCollaboration Revenue8,013,000USD0000950170-23-062136
    Q3 2023Quarterly · 2023-09-30ProductServices29,906,000USD0000950170-23-062136
    Q2 2023Quarterly · 2023-06-30ProductCollaboration Revenue17,536,000USD0000950170-23-037234
    Q2 2023Quarterly · 2023-06-30ProductServices31,390,000USD0000950170-23-037234
    Q1 2023Quarterly · 2023-03-31ProductCollaboration Revenue9,118,000USD0000950170-23-017250
    Q1 2023Quarterly · 2023-03-31ProductServices28,529,000USD0000950170-23-017250
    FY 2022Yearly · 2022-12-31SegmentImmune Medicine Business98,164,000USD0000950170-25-030913
    FY 2022Yearly · 2022-12-31SegmentMrd Business87,144,000USD0000950170-25-030913
    FY 2022Yearly · 2022-12-31ProductCollaboration Revenue66,387,000USD0000950170-24-023095
    FY 2022Yearly · 2022-12-31ProductImmune Medicine Service Revenue700,000USD0000950170-24-023095
    FY 2022Yearly · 2022-12-31ProductRegulatory Milestone Revenue6,000,000USD0000950170-24-023095
    FY 2022Yearly · 2022-12-31ProductServices112,921,000USD0000950170-24-023095
    Q3 2022Quarterly · 2022-09-30ProductCollaboration Revenue21,320,000USD0000950170-23-062136
    Q3 2022Quarterly · 2022-09-30ProductServices26,510,000USD0000950170-23-062136
    FY 2021Yearly · 2021-12-31ProductCollaboration Revenue63,651,000USD0000950170-24-023095
    FY 2021Yearly · 2021-12-31ProductRegulatory Milestone Revenue10,000,000USD0000950170-24-023095
    FY 2021Yearly · 2021-12-31ProductServices80,693,000USD0000950170-24-023095
    FY 2020Yearly · 2020-12-31ProductCollaboration Revenue53,526,000USD0000950170-23-002792
    FY 2020Yearly · 2020-12-31ProductRegulatory Milestone Revenue2,500,000USD0000950170-23-002792
    FY 2020Yearly · 2020-12-31ProductServices42,356,000USD0000950170-23-002792
    FY 2019Yearly · 2019-12-31ProductDevelopment Revenue Regulatory Milestones2,000,000USD0001564590-22-005228
    FY 2019Yearly · 2019-12-31ProductDevelopment Support Revenue39,552,000USD0001564590-22-005228
    FY 2019Yearly · 2019-12-31ProductSequencing Revenue43,519,000USD0001564590-22-005228
    FY 2018Yearly · 2018-12-31ProductDevelopment Revenue Regulatory Milestones10,000,000USD0001564590-21-008124
    FY 2018Yearly · 2018-12-31ProductDevelopment Support Revenue12,685,000USD0001564590-21-008124
    FY 2018Yearly · 2018-12-31ProductSequencing Revenue32,978,000USD0001564590-21-008124

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.